Meghan R Flanagan1,2, David R Doody3, Jenna Voutsinas4,5, Qian Wu4,5, Kalyan Banda6,5, Nima Sharifi7,8, Christopher I Li3, Vijayakrishna K Gadi9,10. 1. Breast Section, Department of Surgery, University of Washington, Seattle, WA, USA. mrf22@uw.edu. 2. Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA. mrf22@uw.edu. 3. Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA. 4. Clinical Biostatistics, Fred Hutchinson Cancer Center, Seattle, WA, USA. 5. Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. 6. Division of Medical Oncology, University of Washington, Seattle, WA, USA. 7. Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA. 8. Department of Cancer Biology, GU Malignancies Research Center, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA. 9. Department of Hematology and Oncology, University of Illinois Chicago, Chicago, IL, USA. 10. Translational Oncology Program, University of Illinois Cancer Center, Chicago, IL, USA.
Abstract
BACKGROUND: Homozygous inheritance of a single-nucleotide polymorphism (1245A > C) in HSD3B1 results in an adrenal permissive phenotype of increased adrenal steroid precursor conversion to potent androgens. This is associated with poor outcomes in prostate cancer. We hypothesized that inheritance of the HSD3B1 adrenal permissive genotype would similarly negatively impact breast cancer outcomes. PATIENTS AND METHODS: Germline HSD3B1 was sequenced in 644 postmenopausal women diagnosed between 2004 and 2015 with stage I-III estrogen receptor-positive (ER+), HER2/neu-negative (HER2-) breast cancer enrolled in a population-based study in western Washington. Primary endpoint was distant metastatic recurrence according to genotype. Secondary endpoint was breast cancer-specific survival. Hazard ratios (HR) were calculated using cause-specific Cox regression accounting for competing risks. RESULTS: Adrenal restrictive genotype (homozygous wild type) was most prevalent (47%), followed by heterozygous (44%) and adrenal permissive (9%). There were no significant differences comparing demographic, tumor, or treatment characteristics apart from higher frequency of adrenal permissive genotype among non-Hispanic white participants (p = 0.04). After accounting for competing risks, the cumulative incidence of distant metastatic recurrence (15 events) was significantly higher among participants with adrenal permissive compared with the adrenal restrictive genotype (HR 4.9, 95% CI 1.32-18.4, p = 0.02). The adrenal permissive genotype was also predictive of breast cancer-specific mortality (HR 3.5, 95% CI 1.27-9.59, p = 0.02). CONCLUSIONS: Inheritance of the HSD3B1 adrenal permissive genotype is associated with increased incidence of distant metastasis and higher cause-specific mortality in postmenopausal ER+/HER2- breast cancer. Further research is necessary to understand the effect of excess adrenal androgen metabolism in promoting breast cancer growth and progression.
BACKGROUND: Homozygous inheritance of a single-nucleotide polymorphism (1245A > C) in HSD3B1 results in an adrenal permissive phenotype of increased adrenal steroid precursor conversion to potent androgens. This is associated with poor outcomes in prostate cancer. We hypothesized that inheritance of the HSD3B1 adrenal permissive genotype would similarly negatively impact breast cancer outcomes. PATIENTS AND METHODS: Germline HSD3B1 was sequenced in 644 postmenopausal women diagnosed between 2004 and 2015 with stage I-III estrogen receptor-positive (ER+), HER2/neu-negative (HER2-) breast cancer enrolled in a population-based study in western Washington. Primary endpoint was distant metastatic recurrence according to genotype. Secondary endpoint was breast cancer-specific survival. Hazard ratios (HR) were calculated using cause-specific Cox regression accounting for competing risks. RESULTS: Adrenal restrictive genotype (homozygous wild type) was most prevalent (47%), followed by heterozygous (44%) and adrenal permissive (9%). There were no significant differences comparing demographic, tumor, or treatment characteristics apart from higher frequency of adrenal permissive genotype among non-Hispanic white participants (p = 0.04). After accounting for competing risks, the cumulative incidence of distant metastatic recurrence (15 events) was significantly higher among participants with adrenal permissive compared with the adrenal restrictive genotype (HR 4.9, 95% CI 1.32-18.4, p = 0.02). The adrenal permissive genotype was also predictive of breast cancer-specific mortality (HR 3.5, 95% CI 1.27-9.59, p = 0.02). CONCLUSIONS: Inheritance of the HSD3B1 adrenal permissive genotype is associated with increased incidence of distant metastasis and higher cause-specific mortality in postmenopausal ER+/HER2- breast cancer. Further research is necessary to understand the effect of excess adrenal androgen metabolism in promoting breast cancer growth and progression.
Authors: Jason W D Hearn; Ghada AbuAli; Chad A Reichard; Chandana A Reddy; Cristina Magi-Galluzzi; Kai-Hsiung Chang; Rachel Carlson; Laureano Rangel; Kevin Reagan; Brian J Davis; R Jeffrey Karnes; Manish Kohli; Donald Tindall; Eric A Klein; Nima Sharifi Journal: Lancet Oncol Date: 2016-08-27 Impact factor: 41.316
Authors: Matthew J Sikora; Kevin E Cordero; Jose M Larios; Michael D Johnson; Marc E Lippman; James M Rae Journal: Breast Cancer Res Treat Date: 2008-06-04 Impact factor: 4.872
Authors: Lu Chen; Linda S Cook; Mei-Tzu C Tang; Peggy L Porter; Deirdre A Hill; Charles L Wiggins; Christopher I Li Journal: Breast Cancer Res Treat Date: 2016-05-24 Impact factor: 4.872
Authors: Jason W D Hearn; Wanling Xie; Mari Nakabayashi; Nima Almassi; Chad A Reichard; Mark Pomerantz; Philip W Kantoff; Nima Sharifi Journal: JAMA Oncol Date: 2018-04-01 Impact factor: 31.777
Authors: Megan L Kruse; Mona Patel; Jeffrey McManus; Yoon-Mi Chung; Xiuxiu Li; Wei Wei; Peter S Bazeley; Fumihiko Nakamura; Aimalie Hardaway; Erinn Downs; Sarat Chandarlapaty; Mathew Thomas; Halle Cf Moore; George T Budd; W H Wilson Tang; Stanley L Hazen; Aaron Bernstein; Serena Nik-Zainal; Jame Abraham; Nima Sharifi Journal: JCI Insight Date: 2021-10-22